Employees: 11-50
Total raised: $90M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | LAV | lavfund.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.02.2021 | Series B | $90M | - |
Mentions in press and media 9
| Date | Title | Description |
| 24.03.2025 | Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics | Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical co... |
| 11.01.2025 | Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity | Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau No treatment-related severe adverse events (AEs), with only 4% discontinuation ... |
| 30.09.2024 | Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer | Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial m... |
| 05.06.2024 | Regor to Present at the Goldman Sachs 45th Annual Global Healthcare Conference | CAMBRIDGE, Mass., June 5, 2024 /PRNewswire/ -- Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Thursd... |
| 08.03.2024 | Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity | CAMBRIDGE, Mass., March 8, 2024 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery engine and differentiated clinical development pipeline... |
| 08.12.2023 | Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy | RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study. Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have ... |
| 28.12.2021 | Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology | SHANGHAI, Dec. 28, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans ... |
| 10.12.2021 | After investing in their Series B, Lilly bags a license for a batch of metabolic candidates | Eli Lilly will license in Regor Therapeutics therapies for metabolic disorders, as a part of an agreement announced Friday that will give the Chinese biotech an upfront payment of up to $50 million, part of which is an eq... |
| 19.02.2021 | Regor Therapeutics Closes $90M Series B Financing | Regor Therapeutics, a Shangai, China-based clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, closed a $90m Series B financing. The round was led... |